Article
Novel compound shows promise for dry eye in proof-of-concept study
Author(s):
Topical drug for the treatment of dry eye disease sees potential
Eric D. Donnenfeld, MD, FAAO, shares results from an ex-U.S. proof-of-concept study investigating a novel, small peptide anti-integrin topical therapy (ALG-1007, Allegro Ophthalmics) for the treatment of dry eye disease. He presented his research at the 2019 annual ASCRS meeting in San Diego.
RELATED: Sustained-release implant promising for long-term IOP reduction
Related Videos
Related Content
